HIGH SARS-COV-2 SEROPREVALENCE IN KARAGANDA, KAZAKHSTAN BEFORE THE LAUNCH OF COVID-19 VACCINATION

Simple item page
dc.contributor.authorKadyrova, Irina
dc.contributor.authorYegorov, Sergey
dc.contributor.authorNegmetzhanov, Baurzhan
dc.contributor.authorKolesnikova, Yevgeniya
dc.contributor.authorKolesnichenko, Svetlana
dc.contributor.authorKorshukov, Ilya
dc.contributor.authorAkhmaltdinova, Lyudmila
dc.contributor.authorVazenmiller, Dmitriy
dc.contributor.authorStupina, Yelena
dc.contributor.authorKabildina, Naylya
dc.contributor.authorAshimova, Assem
dc.contributor.authorRaimbekova, Aigul
dc.contributor.authorTurmukhambetova, Anar
dc.contributor.authorMiller, Matthew S.
dc.contributor.authorHortelano, Gonzalo
dc.contributor.authorBabenko, Dmitriy
dc.date.accessioned2022-11-30T04:45:30Z
dc.date.available2022-11-30T04:45:30Z
dc.date.issued2022-07-27
dc.description.abstractCOVID-19 exposure in Central Asia appears underestimated and SARS-CoV-2 seroprevalence data are urgently needed to inform ongoing vaccination efforts and other strategies to mitigate the regional pandemic. Here, in a pilot serologic study we assessed the prevalence of SARS-CoV-2 antibody-mediated immunity in a multi-ethnic cohort of public university employees in Karaganda, Kazakhstan. Asymptomatic subjects (n = 100) were recruited prior to their first COVID-19 vaccination. Questionnaires were administered to capture a range of demographic and clinical characteristics. Nasopharyngeal swabs were collected for SARS-CoV-2 RT-qPCR testing. Serological assays were performed to detect spike (S)- reactive IgG and IgA and to assess virus neutralization. Pre-pandemic samples were used to validate the assay positivity thresholds. S-IgG and -IgA seropositivity rates among SARSCoV- 2 PCR-negative participants (n = 100) were 42% (95% CI [32.2–52.3]) and 59% (95% CI [48.8–69.0]), respectively, and 64% (95% CI [53.4–73.1]) of the cohort tested positive for at least one of the antibodies. S-IgG titres correlated with virus neutralization activity, detectable in 49% of the tested subset with prior COVID-19 history. Serologically confirmed history of COVID-19 was associated with Kazakh ethnicity, but not with other ethnic minorities present in the cohort, and self-reported history of respiratory illness since March 2020. Overall, SARS-CoV-2 exposure in this cohort was ~15-fold higher compared to the reported all-time national and regional COVID-19 prevalence, consistent with recent studies of excess infection and death in Kazakhstan. Continuous serological surveillance provides important insights into COVID-19 transmission dynamics and may be used to better inform the regional public health response.en_US
dc.identifier.citationKadyrova, I., Yegorov, S., Negmetzhanov, B., Kolesnikova, Y., Kolesnichenko, S., Korshukov, I., Akhmaltdinova, L., Vazenmiller, D., Stupina, Y., Kabildina, N., Ashimova, A., Raimbekova, A., Turmukhambetova, A., Miller, M. S., Hortelano, G., & Babenko, D. (2022). High SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination. PLOS ONE, 17(7), e0272008. https://doi.org/10.1371/journal.pone.0272008en_US
dc.identifier.urihttp://nur.nu.edu.kz/handle/123456789/6840
dc.language.isoenen_US
dc.publisherPLOS ONEen_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectType of access: Open Accessen_US
dc.subjectSARS-CoV-2en_US
dc.subjectCOVID-19en_US
dc.subjectKaragandaen_US
dc.subjectvaccinationen_US
dc.titleHIGH SARS-COV-2 SEROPREVALENCE IN KARAGANDA, KAZAKHSTAN BEFORE THE LAUNCH OF COVID-19 VACCINATIONen_US
dc.typeArticleen_US
workflow.import.sourcescience

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
journal.pone.0272008.pdf
Size:
935.59 KB
Format:
Adobe Portable Document Format
Description:
article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
6.28 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Articles